Zenas BioPharma

Zenas BioPharma

Zenas BioPharma was founded by biopharmaceutical veteran Lonnie Moulder, who serves as CEO and Chairman. The firm focuses exclusively on autoimmune diseases, a departure from broader biotech strategies. Wealth origin for the firm itself is not publicly disclosed; Moulder previously led Tesaro and other drug developers. (per firm website) The strategy centers on two late-stage franchises: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B-cell activity, and orelabrutinib, a CNS-penetrant BTK inhibitor. Both address multiple autoimmune indications. The firm pursues partnerships alongside internal development to expand its pipeline. (per firm website) Zenas operates from Waltham, Massachusetts, with no other offices disclosed. The executive team includes Patricia Allen, James Boylan, Patrick Enright, Hongbo Lu, Jake Nunn, and John Orloff. Team size is not publicly quantified. The firm positions itself with global capabilities but has not disclosed recent funding rounds or a recent operational event in the last 24 months by public record. Zenas BioPharma is structured as a commercially focused biotech company rather than a venture or family office. Its distinctive model pairs an experienced management team with a concentrated pipeline, operating with a sense of urgency to bring two therapies to market. No spinouts or adjacent vehicles have been disclosed.